FDA greenlights Roivant's oral drug Lisraya for rare skin-muscle disease

The FDA approved Roivant and its unit Priovant's medication brepocitinib, sold as Lisraya, as a treatment for dermatomyositis. The condition affects tens of thousands in the United States and currently relies on high-dose steroids.